Increased blood myeloid dendritic cells and dendritic cell-poietins in Langerhans cell histiocytosis

Alexandre Rolland, Lydie Guyon, Michelle Gill, Yi Hong Cai, Jacques Banchereau, Kenneth McClain, A. Karolina Palucka

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Langerhans cell histiocytosis (LCH), previously known as histiocytosis X, is a reactive proliferative disease of unknown pathogenesis. Current therapies are based on nonspecific immunosuppression. Because multiple APCs, including Langerhans cells and macrophages, are involved in the lesion formation, we surmised that LCH is a disease of myeloid blood precursors. We found that lin- HLA-DR+CD11c-+ precursors of dendritic cells, able to give rise to either Langerhans cells or macrophages, are significantly (p = 0.004) increased in the blood of LCH patients. The analysis of serum cytokines in 24 patients demonstrated significantly elevated levels of hemopoietic cytokines such as fms-like tyrosine kinase ligand (FLT3-L, a dendritic cell-mobilizing factor, ∼2-fold) and M-CSF (∼4-fold). Higher levels of these cytokines correlated with patients having more extensive disease. Serum levels of FLT3-L and M-CSF were highest in high risk patients with extensive skin and/or multisystem involvement. Finally, patients with bone lesions had relatively higher levels of M-CSF and of stem cell factor. Thus, early hemopoietic cytokines such as FLT3-L, stem cell factor, and M-CSF maybe relevant in LCH pathogenesis and might be considered as novel therapeutic targets.

Original languageEnglish (US)
Pages (from-to)3067-3071
Number of pages5
JournalJournal of Immunology
Volume174
Issue number5
StatePublished - Mar 1 2005

Fingerprint

Langerhans Cell Histiocytosis
Myeloid Cells
Macrophage Colony-Stimulating Factor
Dendritic Cells
Blood Cells
Cytokines
Stem Cell Factor
Langerhans Cells
Macrophages
Vascular Endothelial Growth Factor Receptor-1
Hematologic Diseases
HLA-DR Antigens
Serum
Immunosuppression
Ligands
Bone and Bones
Skin
Therapeutics

ASJC Scopus subject areas

  • Immunology

Cite this

Rolland, A., Guyon, L., Gill, M., Cai, Y. H., Banchereau, J., McClain, K., & Palucka, A. K. (2005). Increased blood myeloid dendritic cells and dendritic cell-poietins in Langerhans cell histiocytosis. Journal of Immunology, 174(5), 3067-3071.

Increased blood myeloid dendritic cells and dendritic cell-poietins in Langerhans cell histiocytosis. / Rolland, Alexandre; Guyon, Lydie; Gill, Michelle; Cai, Yi Hong; Banchereau, Jacques; McClain, Kenneth; Palucka, A. Karolina.

In: Journal of Immunology, Vol. 174, No. 5, 01.03.2005, p. 3067-3071.

Research output: Contribution to journalArticle

Rolland, A, Guyon, L, Gill, M, Cai, YH, Banchereau, J, McClain, K & Palucka, AK 2005, 'Increased blood myeloid dendritic cells and dendritic cell-poietins in Langerhans cell histiocytosis', Journal of Immunology, vol. 174, no. 5, pp. 3067-3071.
Rolland A, Guyon L, Gill M, Cai YH, Banchereau J, McClain K et al. Increased blood myeloid dendritic cells and dendritic cell-poietins in Langerhans cell histiocytosis. Journal of Immunology. 2005 Mar 1;174(5):3067-3071.
Rolland, Alexandre ; Guyon, Lydie ; Gill, Michelle ; Cai, Yi Hong ; Banchereau, Jacques ; McClain, Kenneth ; Palucka, A. Karolina. / Increased blood myeloid dendritic cells and dendritic cell-poietins in Langerhans cell histiocytosis. In: Journal of Immunology. 2005 ; Vol. 174, No. 5. pp. 3067-3071.
@article{d425763775874eeb90dc3d882ba098ed,
title = "Increased blood myeloid dendritic cells and dendritic cell-poietins in Langerhans cell histiocytosis",
abstract = "Langerhans cell histiocytosis (LCH), previously known as histiocytosis X, is a reactive proliferative disease of unknown pathogenesis. Current therapies are based on nonspecific immunosuppression. Because multiple APCs, including Langerhans cells and macrophages, are involved in the lesion formation, we surmised that LCH is a disease of myeloid blood precursors. We found that lin- HLA-DR+CD11c-+ precursors of dendritic cells, able to give rise to either Langerhans cells or macrophages, are significantly (p = 0.004) increased in the blood of LCH patients. The analysis of serum cytokines in 24 patients demonstrated significantly elevated levels of hemopoietic cytokines such as fms-like tyrosine kinase ligand (FLT3-L, a dendritic cell-mobilizing factor, ∼2-fold) and M-CSF (∼4-fold). Higher levels of these cytokines correlated with patients having more extensive disease. Serum levels of FLT3-L and M-CSF were highest in high risk patients with extensive skin and/or multisystem involvement. Finally, patients with bone lesions had relatively higher levels of M-CSF and of stem cell factor. Thus, early hemopoietic cytokines such as FLT3-L, stem cell factor, and M-CSF maybe relevant in LCH pathogenesis and might be considered as novel therapeutic targets.",
author = "Alexandre Rolland and Lydie Guyon and Michelle Gill and Cai, {Yi Hong} and Jacques Banchereau and Kenneth McClain and Palucka, {A. Karolina}",
year = "2005",
month = "3",
day = "1",
language = "English (US)",
volume = "174",
pages = "3067--3071",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "5",

}

TY - JOUR

T1 - Increased blood myeloid dendritic cells and dendritic cell-poietins in Langerhans cell histiocytosis

AU - Rolland, Alexandre

AU - Guyon, Lydie

AU - Gill, Michelle

AU - Cai, Yi Hong

AU - Banchereau, Jacques

AU - McClain, Kenneth

AU - Palucka, A. Karolina

PY - 2005/3/1

Y1 - 2005/3/1

N2 - Langerhans cell histiocytosis (LCH), previously known as histiocytosis X, is a reactive proliferative disease of unknown pathogenesis. Current therapies are based on nonspecific immunosuppression. Because multiple APCs, including Langerhans cells and macrophages, are involved in the lesion formation, we surmised that LCH is a disease of myeloid blood precursors. We found that lin- HLA-DR+CD11c-+ precursors of dendritic cells, able to give rise to either Langerhans cells or macrophages, are significantly (p = 0.004) increased in the blood of LCH patients. The analysis of serum cytokines in 24 patients demonstrated significantly elevated levels of hemopoietic cytokines such as fms-like tyrosine kinase ligand (FLT3-L, a dendritic cell-mobilizing factor, ∼2-fold) and M-CSF (∼4-fold). Higher levels of these cytokines correlated with patients having more extensive disease. Serum levels of FLT3-L and M-CSF were highest in high risk patients with extensive skin and/or multisystem involvement. Finally, patients with bone lesions had relatively higher levels of M-CSF and of stem cell factor. Thus, early hemopoietic cytokines such as FLT3-L, stem cell factor, and M-CSF maybe relevant in LCH pathogenesis and might be considered as novel therapeutic targets.

AB - Langerhans cell histiocytosis (LCH), previously known as histiocytosis X, is a reactive proliferative disease of unknown pathogenesis. Current therapies are based on nonspecific immunosuppression. Because multiple APCs, including Langerhans cells and macrophages, are involved in the lesion formation, we surmised that LCH is a disease of myeloid blood precursors. We found that lin- HLA-DR+CD11c-+ precursors of dendritic cells, able to give rise to either Langerhans cells or macrophages, are significantly (p = 0.004) increased in the blood of LCH patients. The analysis of serum cytokines in 24 patients demonstrated significantly elevated levels of hemopoietic cytokines such as fms-like tyrosine kinase ligand (FLT3-L, a dendritic cell-mobilizing factor, ∼2-fold) and M-CSF (∼4-fold). Higher levels of these cytokines correlated with patients having more extensive disease. Serum levels of FLT3-L and M-CSF were highest in high risk patients with extensive skin and/or multisystem involvement. Finally, patients with bone lesions had relatively higher levels of M-CSF and of stem cell factor. Thus, early hemopoietic cytokines such as FLT3-L, stem cell factor, and M-CSF maybe relevant in LCH pathogenesis and might be considered as novel therapeutic targets.

UR - http://www.scopus.com/inward/record.url?scp=14044270749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14044270749&partnerID=8YFLogxK

M3 - Article

VL - 174

SP - 3067

EP - 3071

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 5

ER -